Table 3 Clinical trials targeting MYC
From: MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies
Type | Mechanism | Condition(s) | Compound | Phase | NCT number |
|---|---|---|---|---|---|
Direct MYC inhibition | siRNA against the MYC | Hepatocellular Carcinoma | DCR-MYC | Phase 1 Phase 2 | NCT02314052 |
Inhibits MYC/MAX dimerization Inhibition of E-box binding | Advanced Solid Tumors Non-small-cell lung carcinoma (NSCLC) Triple-negative Breast Cancer | OMO-103 | Phase 1 Phase 2 | NCT04808362 | |
Inhibits MYC/MAX dimerization | Neoplasms | OMO-1 | Phase 1 Phase 2 | NCT03138083 | |
Downregulation of MYC | Ischemic Stroke | miR-494 | - | NCT03577093 | |
Interrupts the translation of MYC gene | Neoplasms | AVI-4126 (RESTEN-NG) | Phase 1 | NCT00343148 | |
Indirect MYC inhibition | Alteration of MYC translation (BET Bromodomain inhibitors) | Castration-Resistant Prostate Carcinoma Metastatic Prostate Adenocarcinoma Metastatic Prostate Small Cell Carcinoma Stage IV Prostate Cancer AJCC v8 Stage IVA Prostate Cancer AJCC v8 Stage IVB Prostate Cancer AJCC v8 | ZEN-3694 | Phase 2 | NCT04471974 |
Solid Tumor Lymphoma Brain Tumor | BMS-986158 | Phase 1 | NCT03936465 | ||
Lymphoma, Non- Hodgkin | CC-95775 (FT-1101) | Phase 1 | NCT04089527 | ||
Diffuse Large B-cell Lymphoma (DLBCL) High-Grade B-cell Lymphoma | RO6870810 | Phase 1 | NCT03255096 | ||
Neoplasms | GSK525762 | Phase 2 | NCT01943851 | ||
Myelofibrosis Primary Myelofibrosis Post-polycythemia Vera Myelofibrosis Post-essential Thrombocythemia Myelofibrosis | CPI-0610 | Phase 3 | NCT04603495 | ||
Metastatic Malignant Solid Neoplasm Recurrent Malignant Solid Neoplasm Recurrent Platinum-Resistant Ovarian Carcinoma Refractory Ovarian Carcinoma | ZEN-3694 | Phase 1 | NCT04840589 | ||
Malignant Solid Tumors Lymphoma Ovarian Cancer Breast Cancer Pancreatic Cancer Prostate Cancer | AZD5153 | Phase 1 | NCT03205176 | ||
Neoplasms NUT Carcinoma | BI 894999 | Phase 1 | NCT02516553 | ||
AML Including AML de Novo and AML Secondary to MDS DLBCL | Birabresib (MK-8628, OTX015) | Phase 1 | NCT02698189 | ||
MCL-1 inhibitor | Relapsed or Refractory AML | AZD5991 | Phase 1 Phase 2 | NCT03218683 | |
AML | S64315 (MIK665) | Phase 1 Phase 2 | NCT04629443 | ||
Relapsed or Refractory Multiple Myeloma Relapsed or Refractory AML | AMG 176 | Phase 1 | NCT02675452 | ||
Multiple Myeloma Non-Hodgkins Lymphoma Myelodysplastic Syndrome | AMG 397 | Phase 1 | NCT03465540 | ||
Inhibiting BCR-signalling | Prolymphocytic Leukemia Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia | Ibrutinib | Phase 1 | NCT02303392 | |
Lymphoma, B-Cell Small Lymphocytic Lymphoma CLL Waldenstrom Macroglobulinemia Mantle Cell Lymphoma Diffuse Large B Cell Lymphoma Richter's Transformation Follicular Lymphoma Marginal Zone Lymphoma | ARQ 531 | Phase 1 Phase 2 | NCT03162536 | ||
Epigenetic silencing (HDAC inhibitors) | Diffuse Large B-cell Lymphoma | Tucidinostat | Phase 3 | NCT04231448 | |
Relapsed and refractory lymphoma | Entinostat | Phase 2 | NCT03179930 | ||
PI3K inhibitor | B Cells-Tumors B Cell Chronic Lymphocytic Leukemia Follicular Lymphoma Mantle Cell Lymphoma Large B-Cell Diffuse Lymphoma of Bone (Diagnosis) | Idelalisib | Phase 1 | NCT03151057 | |
Dual inhibitor of PI3Kδ and CK1ε | CLL B-cell Non-Hodgkin Lymphoma | TGR-1202 | Phase 1 | NCT03283137 | |
Dual inhibitor of PI3Kδ and DNA-PK | Diffuse Large B Cell Lymphoma Follicular Lymphoma CLL Small Lymphocytic Leukemia B Cell Lymphoma Marginal Zone Lymphoma Waldenstrom Macroglobulinemia Peripheral T Cell Lymphoma | BR101801 | Phase 1 | NCT04018248 | |
Dual inhibitor of PI3Kδ and HDACs | Relapsed and/or Refractory DLBCL With MYC Alterations | Fimepinostat (CUDC-907) | Phase 2 | NCT02674750 | |
Inhibitor of CDK1, CDK2, CDK5 and CDK9 | Advanced or Metastatic Breast Cancer Triple Negative Breast Cancer | Dinaciclib | Phase 1 | NCT01676753 | |
CDK9 inhibitor | Relapsed Solid Tumors Refractory Solid Tumors Non-Hodgkin Lymphoma | KB-0742 | Phase 1 | NCT04718675 | |
Multi kinase inhibitor: inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3 | AML ALL Blast Crisis MDS Multiple Myeloma | TG02 | Phase 1 | NCT01204164 | |
G-quadraplex stabilizer at MYC promoter | AML High Risk Myelodysplasia | APTO-253 | Phase 1 | NCT02267863 | |
Advanced Solid Tumors Lymphoma | CX-3543 | Phase 1 | NCT00955786 |